Recent Finacing
Recent Raise
RuiYi develops monoclonal antibodies targeting GPCRs using its iCAPS discovery platform, advancing lead programs RYI‑008 (anti‑IL‑6) and RYI‑018 (anti‑CB1) from La Jolla and Zhangjiang labs.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors